Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease

Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease

Several studies have shown the renoprotective effects of pentoxifylline in the treatment of chronic kidney disease (CKD). This study was conducted to examine whether there was an increased benefit of including pentoxifylline with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II recep...

Full description

Bibliographic Details
Main Authors:	Ping-Min Chen, Tai-Shuan Lai, Ping-Yu Chen, Chun-Fu Lai, VinCent Wu, Wen-Chih Chiang, Yung-Ming Chen, Kwan-Dun Wu, Tun-Jun Tsai
Format:	Article
Language:	English
Published:	Elsevier 2014-04-01
Series:	Journal of the Formosan Medical Association
Subjects:	angiotensin-converting enzyme inhibitors angiotensin II receptor blockers chronic kidney disease pentoxifylline renal outcome
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664614000072

Similar Items

Renoprotective effect of pentoxifylline in advanced chronic kidney disease
by: Chih-Chin Kao
Published: (2015-01-01)

Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery
by: Shao-Yu Yang, et al.
Published: (2021-04-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01)

Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update
by: Yung-Ming Chen, et al.
Published: (2017-11-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

The Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers on Clinical Outcomes of Acute Kidney Disease Patients: A Systematic Review and Meta-Analysis
by: Jui-Yi Chen, et al.
Published: (2021-07-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Renin-angiotensin system blockers and COVID-19
by: Emmanuelle Vidal-Petiot, et al.
Published: (2021-06-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Angiotensin receptor blocker-induced bilateral ciliochoroidal effusion
by: Kanika Aggarwal, et al.
Published: (2020-01-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
by: Lai CC, et al.
Published: (2018-03-01)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
by: Seok Hui Kang, et al.
Published: (2023-05-01)

Perspectives of using angiotensin receptor antagonists
by: V V Fomin
Published: (2009-06-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Comparison of Angiotensin‐Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial
by: Sean van Diepen, et al.
Published: (2018-10-01)

The Effect of Pentoxifylline in Reducing Proteinuria in Patients with Diabetic Nephropathy Treated with ACEI or ARB
by: Iranparvar, et al.
Published: (2017-10-01)

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
by: Na Jia, et al.
Published: (2021-09-01)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
by: Ju Hwan Kim, et al.
Published: (2020-12-01)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
by: Dan-Dan Qiu, et al.
Published: (2018-01-01)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
by: Athanasios Feidakis, et al.
Published: (2021-01-01)

Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease
by: Pei-Tzu Wang, et al.
Published: (2012-09-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System
by: Jaejin An, et al.
Published: (2021-02-01)

Angiotensin receptor blockers in heart failure after the ELITE II trial
by: Willenheimer Ronnie
Published: (2000-09-01)

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
by: Ram CV
Published: (2011-05-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
by: Emmanuel Oger, et al.
Published: (2022-04-01)

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
by: Jenny I. Shen, et al.
Published: (2017-06-01)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
by: Paranjpe R, et al.
Published: (2020-10-01)

Renoprotective impact of angiotensin 1-7: Is it certain?
by: Mehdi Nematbakhsh
Published: (2019-01-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease
by: Ming-Hsien Wu, et al.
Published: (2020-04-01)

The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy
by: Danai-Thomais Kostourou, et al.
Published: (2022-07-01)